BCL2 and acute myeloid leukemia: Furthermore, Ye et al. proved in vitro and in vivo that DNA hypermethylation-induced miR-182 silencing targets BCL2 and HOXA9 to accelerate acute myeloid leukemia progression, thus providing a potential selective therapeutic target for acute myeloid leukemia patients (Ye et al., 2023).